author-photo

Molly A. Taylor

Case Western Reserve University
AstraZeneca

31

Papers

1111

Citations

Citation Trend

Filter By

Papers (23) Sort By

Journal Conference Others

Macrophage activation status rather than repolarization is associated with enhanced checkpoint activity in combination with PI3Kg inhibition.

2021 Molecular Cancer Therapeutics
Show All
- Source
- Cite
- Save
Citations (1)
VEGF pathway inhibition potentiates PARP inhibitor efficacy in ovarian cancer independent of BRCA status

2021 Journal of Hematology & Oncology
Show All
- Source
- Cite
- Save
Citations (1)
Heat Inactivation of Clinical COVID-19 Samples on an Industrial Scale for Low Risk and Efficient High-throughput qRT-PCR Diagnostic Testing

2021
Show All
- Source
- Cite
- Save
Citations (0)
Longitudinal immune characterization of syngeneic tumor models to enable model selection for immune oncology drug discovery

2019 Journal for ImmunoTherapy of Cancer
Show All
- Source
- Cite
- Save
Citations (18)
Abstract 2713: Discovery and characterization of AZD8701, a high affinity antisense oligonucleotide targeting FOXP3 to relieve immunosuppression in cancer

2019 Cancer Research
Show All
- Source
- Cite
- Save
Citations (5)
Abstract 100: Novel selective PI3Kγ inhibitor AZD3458 promotes anti-tumor immune responses and reverts resistance to immunotherapy in checkpoint blockade refractory preclinical models

2019 Tumor Biology
Show All
- Source
- Cite
- Save
Citations (2)
PI3Kα/δ inhibition promotes anti-tumor immunity through direct enhancement of effector CD8+ T-cell activity

2018 Journal for ImmunoTherapy of Cancer
Show All
- Source
- Cite
- Save
Citations (37)
Abstract 2816: Patient derived ovarian cancer xenograft (OC-PDX) to study the response of the PARP inhibitor olaparib

2018 Cancer Research
Show All
- Source
- Cite
- Save
Citations (1)
Abstract 5561: High-affinity antisense oligonucleotides targeting Foxp3 inhibit immunosuppressive function of regulatory T-cells and produce antitumor effects in syngeneic tumor models

2018 Cancer Research
Show All
- Source
- Cite
- Save
Citations (1)
Combination of dual mTORC1/2 inhibition and immune-checkpoint blockade potentiates anti-tumour immunity

2018 OncoImmunology
Show All
- Source
- Cite
- Save
Citations (19)